Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Creative Educational Concepts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Creative Educational Concepts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast Cancer

50:54
 
Share
 

Manage episode 433130543 series 2870185
Content provided by Creative Educational Concepts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Creative Educational Concepts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Patients with triple-negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents which may improve patient outcomes. However, clinicians cannot implement them into practice appropriately or may be hesitant to use them altogether.

In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
Learn more: https://www.ceconcepts.com/activity/advancements-and-applications-of-antibody-drug-conjugates-in-her2-negative-breast-cancer/

  continue reading

35 episodes

Artwork
iconShare
 
Manage episode 433130543 series 2870185
Content provided by Creative Educational Concepts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Creative Educational Concepts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Patients with triple-negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents which may improve patient outcomes. However, clinicians cannot implement them into practice appropriately or may be hesitant to use them altogether.

In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
Learn more: https://www.ceconcepts.com/activity/advancements-and-applications-of-antibody-drug-conjugates-in-her2-negative-breast-cancer/

  continue reading

35 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play